Literature DB >> 15213285

Arterial calcifications and bone histomorphometry in end-stage renal disease.

Gérard M London1, Caroline Marty, Sylvain J Marchais, Alain P Guerin, Fabien Metivier, Marie-Christine de Vernejoul.   

Abstract

Arterial calcification (AC) is a common complication of end-stage renal disease (ESRD). The mechanisms responsible are complex, including disturbances of mineral metabolism and active expression of various mineral-regulating proteins. An inverse relationship between AC and bone density has been documented in uremic patients. In the study presented here, which included 58 patients with ESRD on hemodialysis (HD), bone-histomorphometry characteristics were compared with the AC scores (0 to 4) determined according to the number of arterial sites with calcifications. Patients with AC scores of 0 (no calcifications), or 1 or 2 (mild calcifications) had similar serum parathyroid hormone levels and bone histomorphometry, with larger osteoclast resorption, higher osteoclast numbers, and larger osteoblastic and double tertracycline-labeled surfaces. In contrast, patients with high AC scores (3 and 4) were characterized by lower serum parathyroid hormone, low osteoclast numbers and osteoblastic surfaces, smaller or absent double tetracycline-labeled surfaces, and high percentages of aluminum-stained surfaces. According to multivariate analysis, AC score was positively associated with age (P < 0.0001), daily dose of calcium-containing phosphate binders (P = 0.009), and bone aluminum-stained surfaces (P = 0.037), and an inverse correlation was observed with osteoblastic surfaces (P = 0.001). A high AC score is associated with bone histomorphometry suggestive of low bone activity and adynamic bone disease. These findings suggest that therapeutic interventions associated with excessive lowering of parathyroid activity (parathyroidectomy, excessive calcium or aluminum load) favor lower bone turnover and adynamic bone disease, which could influence the development and progression of AC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213285     DOI: 10.1097/01.asn.0000129337.50739.48

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  125 in total

1.  Cholesterol in vascular and valvular calcification.

Authors:  L L Demer
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

Review 2.  [Indications for parathyroidectomy in renal hyperparathyroidism: comments on the significance of new therapeutics].

Authors:  C Dotzenrath
Journal:  Chirurg       Date:  2010-10       Impact factor: 0.955

3.  Bone mineral density in children with chronic renal failure.

Authors:  Simon Waller; Deborah Ridout; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2006-09-15       Impact factor: 3.714

Review 4.  Pathophysiology of Vascular Calcification.

Authors:  Neal X Chen; Sharon M Moe
Journal:  Curr Osteoporos Rep       Date:  2015-12       Impact factor: 5.096

5.  Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?

Authors:  S Pelletier; C B Confavreux; J Haesebaert; F Guebre-Egziabher; J Bacchetta; M-C Carlier; L Chardon; M Laville; R Chapurlat; G M London; M-H Lafage-Proust; D Fouque
Journal:  Osteoporos Int       Date:  2015-04-25       Impact factor: 4.507

6.  25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification.

Authors:  Ian H de Boer; Bryan Kestenbaum; Abigail B Shoben; Erin D Michos; Mark J Sarnak; David S Siscovick
Journal:  J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 10.121

Review 7.  Effects of treatment of renal osteodystrophy on bone histology.

Authors:  Hartmut H Malluche; Hanna Mawad; Marie-Claude Monier-Faugere
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

Review 8.  The role of bone biopsy in patients with chronic renal failure.

Authors:  Paul D Miller
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

9.  Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease.

Authors:  Madeleine V Pahl; Nosratola D Vaziri; Jun Yuan; Sharon G Adler
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

10.  Cinacalcet is efficacious in pediatric dialysis patients.

Authors:  Douglas M Silverstein; Kanwal K Kher; Asha Moudgil; Mona Khurana; Jennifer Wilcox; Kathleen Moylan
Journal:  Pediatr Nephrol       Date:  2008-02-21       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.